(Q37481714)

20 August 2017

The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size (English)

1 reference

20 August 2017

Guozheng Liu

1

1 reference

20 August 2017

Shuping Dou

2

1 reference

20 August 2017

Minmin Liang

3

1 reference

20 August 2017

Xiangji Chen

4

1 reference

20 August 2017

Mary Rusckowski

5

1 reference

20 August 2017

Donald J Hnatowich

6

1 reference

20 August 2017

language of work or name

1 reference

5 October 2009

1 reference

European Journal of Cancer

20 August 2017

1 reference

20 August 2017

45

1 reference

20 August 2017

17

1 reference

20 August 2017

3098-3103

1 reference

Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

A semiempirical model of tumor pretargeting

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

Localization of human tumour xenografts after i.v. administration of radiolabeled monoclonal antibodies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795388

Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft

2 September 2018

1 reference

12 December 2020

Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results

1 reference

12 December 2020

A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs

1 reference

12 December 2020

Optimizing bispecific antibody pretargeting for use in radioimmunotherapy

1 reference

12 December 2020

Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.

1 reference

12 December 2020

10.1016/J.EJCA.2009.09.007

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19811906

1 reference